Arthritic Therapeutic Market By Product Type (Non-steroidal Anti-inflammatory Drugs (NSAIDs), Disease Modified Anti-rheumatoid Drugs (DMARDs), Biologics, Others), By Application (Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Others): Global Opportunity Analysis and Industry Forecast, 2022 - 2032
The arthritic therapeutic market was valued at $79.5 billion in 2022 and is estimated to reach $136.1 billion by 2032, exhibiting a CAGR of 5.5% from 2023 to 2032. Arthritis therapeutics involves a comprehensive array of medical interventions aimed at alleviating symptoms and managing various forms of arthritis, such as osteoarthritis and rheumatoid arthritis. These therapeutic approaches include pharmaceuticals, biologics, and lifestyle modifications tailored to mitigate pain, reduce inflammation, and enhance joint function. The goal is to improve the overall quality of life for individuals affected by arthritis, addressing the unique challenges posed by joint-related ailments. Arthritis therapeutics reflects a dynamic field that integrates medical advancements, personalized treatment strategies, and innovative solutions to provide effective relief and enhance the long-term well-being of those suffering with arthritis conditions.
The growing prevalence of arthritis conditions, including osteoarthritis, psoriatic arthritis, and rheumatoid arthritis, serves as a significant driver fueling the growth of the arthritic therapeutic market. According to the Center for Disease Control and Prevention (CDC), over 47 million Americans are affected by arthritis, with osteoarthritis impacting approximately 30.8 million individuals and rheumatoid arthritis affecting 1.3 million. This escalating prevalence underscores the pressing need for effective therapeutic interventions to manage symptoms, alleviate pain, and improve joint function. As the prevalence of arthritis conditions continues to rise, the demand for arthritis therapeutics is propelled, leading to a surge in research, development, and innovation within the pharmaceutical industry. Healthcare providers and policymakers increasingly recognize the importance of addressing the growing burden of arthritis, driving investments and initiatives aimed at expanding access to comprehensive arthritis care and advancing treatment options to meet the evolving healthcare needs of affected individuals.
In addition, the growth of the arthritic therapeutic market is propelled by a surge in R&D initiatives and a multitude of drugs in the pipeline. Major players such as Pfizer and Amgen Inc. exemplify this trend. Pfizer's Dekavi, a new molecular entity in Phase 2 trials for Rheumatoid Arthritis, underscores the commitment to innovative solutions. Similarly, Amgen's ABP 654, an investigational biosimilar in Phase 3 clinical trials, demonstrates the pursuit of alternative, cost-effective therapies. These substantial investments by key pharmaceutical companies not only showcase a dedication to addressing unmet medical needs but also indicate a collective industry effort to advance therapeutic options for arthritis patients. As more promising drugs progress through clinical trials, the market is poised for growth, reflecting a positive outlook for enhanced treatment modalities and improved outcomes in arthritis management.
The arthritic therapeutic market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into non-steroidal anti-inflammatory drugs (NSAIDs), disease modified anti-rheumatoid drugs (DMARDs), biologics and others. On the basis of application, the market is segmented into rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, and others. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LA (Brazil, Colombia, Argentina, and rest of LA) and MEA (GCC, South Africa, North Africa and rest of MEA).
The major key players that operate in the global arthritic therapeutic market are AbbVie Inc., Pfizer, Amgen Inc, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Biogen Inc, Celltrion Healthcare Co. Ltd, Sobi Inc. The key players have adopted product launch, product development and product approval as the key strategy to expand their product portfolio.
Key Benefits for Stakeholders
The growing prevalence of arthritis conditions, including osteoarthritis, psoriatic arthritis, and rheumatoid arthritis, serves as a significant driver fueling the growth of the arthritic therapeutic market. According to the Center for Disease Control and Prevention (CDC), over 47 million Americans are affected by arthritis, with osteoarthritis impacting approximately 30.8 million individuals and rheumatoid arthritis affecting 1.3 million. This escalating prevalence underscores the pressing need for effective therapeutic interventions to manage symptoms, alleviate pain, and improve joint function. As the prevalence of arthritis conditions continues to rise, the demand for arthritis therapeutics is propelled, leading to a surge in research, development, and innovation within the pharmaceutical industry. Healthcare providers and policymakers increasingly recognize the importance of addressing the growing burden of arthritis, driving investments and initiatives aimed at expanding access to comprehensive arthritis care and advancing treatment options to meet the evolving healthcare needs of affected individuals.
In addition, the growth of the arthritic therapeutic market is propelled by a surge in R&D initiatives and a multitude of drugs in the pipeline. Major players such as Pfizer and Amgen Inc. exemplify this trend. Pfizer's Dekavi, a new molecular entity in Phase 2 trials for Rheumatoid Arthritis, underscores the commitment to innovative solutions. Similarly, Amgen's ABP 654, an investigational biosimilar in Phase 3 clinical trials, demonstrates the pursuit of alternative, cost-effective therapies. These substantial investments by key pharmaceutical companies not only showcase a dedication to addressing unmet medical needs but also indicate a collective industry effort to advance therapeutic options for arthritis patients. As more promising drugs progress through clinical trials, the market is poised for growth, reflecting a positive outlook for enhanced treatment modalities and improved outcomes in arthritis management.
The arthritic therapeutic market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into non-steroidal anti-inflammatory drugs (NSAIDs), disease modified anti-rheumatoid drugs (DMARDs), biologics and others. On the basis of application, the market is segmented into rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, and others. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LA (Brazil, Colombia, Argentina, and rest of LA) and MEA (GCC, South Africa, North Africa and rest of MEA).
The major key players that operate in the global arthritic therapeutic market are AbbVie Inc., Pfizer, Amgen Inc, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Biogen Inc, Celltrion Healthcare Co. Ltd, Sobi Inc. The key players have adopted product launch, product development and product approval as the key strategy to expand their product portfolio.
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the arthritic therapeutic market analysis from 2022 to 2032 to identify the prevailing arthritic therapeutic market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the arthritic therapeutic market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global arthritic therapeutic market trends, key players, market segments, application areas, and market growth strategies.
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
- Disease Modified Anti-rheumatoid Drugs (DMARDs)
- Biologics
- Others
- Osteoarthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Others
- North America U.S.
- Canada
- Mexico
- Europe Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Latin America Brazil
- Colombia
- Argentina
- Rest Of La
- Middle East and Africa Gcc
- South Africa
- North Africa
- Rest Of Mea
- AbbVie Inc.
- Pfizer Inc.
- Amgen Inc.
- Novartis AG
- Jhonson & Jhonson
- Viatris Inc.
- Bausch Health (Storz Opthalmic Instrument)
- LEO Pharma
- Merck & Co., Inc.
- Celltrion Inc
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter s five forces analysis
3.3.1. Low threat of new entrants
3.3.2. Low threat of substitutes
3.3.3. Low bargaining power of buyers
3.3.4. Moderate bargaining power of suppliers
3.3.5. Low intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rising prevalence of arthritis globally, especially among aging populations
3.4.1.2. Increasing awareness, early diagnosis, and adoption of advanced therapies such as DMARDs and biologics
3.4.1.3. Development and adoption of biosimilars and cost-effective generic alternatives
3.4.2. Restraints
3.4.2.1. High treatment costs, especially for biologics and targeted therapies
3.4.3. Opportunities
3.4.3.1. Growth Opportunities in Emerging Markets
CHAPTER 4: ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Disease Modified Anti-rheumatoid Drugs (DMARDs)
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Biologics
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Others
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Rheumatoid Arthritis
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Osteoarthritis
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Psoriatic Arthritis
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Ankylosing Spondylitis
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Others
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
CHAPTER 6: ARTHRITIC THERAPEUTIC MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by Product Type
6.2.3. Market size and forecast, by Application
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Market size and forecast, by Product Type
6.2.4.1.2. Market size and forecast, by Application
6.2.4.2. Canada
6.2.4.2.1. Market size and forecast, by Product Type
6.2.4.2.2. Market size and forecast, by Application
6.2.4.3. Mexico
6.2.4.3.1. Market size and forecast, by Product Type
6.2.4.3.2. Market size and forecast, by Application
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by Product Type
6.3.3. Market size and forecast, by Application
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Market size and forecast, by Product Type
6.3.4.1.2. Market size and forecast, by Application
6.3.4.2. France
6.3.4.2.1. Market size and forecast, by Product Type
6.3.4.2.2. Market size and forecast, by Application
6.3.4.3. UK
6.3.4.3.1. Market size and forecast, by Product Type
6.3.4.3.2. Market size and forecast, by Application
6.3.4.4. Italy
6.3.4.4.1. Market size and forecast, by Product Type
6.3.4.4.2. Market size and forecast, by Application
6.3.4.5. Spain
6.3.4.5.1. Market size and forecast, by Product Type
6.3.4.5.2. Market size and forecast, by Application
6.3.4.6. Rest of Europe
6.3.4.6.1. Market size and forecast, by Product Type
6.3.4.6.2. Market size and forecast, by Application
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by Product Type
6.4.3. Market size and forecast, by Application
6.4.4. Market size and forecast, by country
6.4.4.1. Japan
6.4.4.1.1. Market size and forecast, by Product Type
6.4.4.1.2. Market size and forecast, by Application
6.4.4.2. China
6.4.4.2.1. Market size and forecast, by Product Type
6.4.4.2.2. Market size and forecast, by Application
6.4.4.3. India
6.4.4.3.1. Market size and forecast, by Product Type
6.4.4.3.2. Market size and forecast, by Application
6.4.4.4. Australia
6.4.4.4.1. Market size and forecast, by Product Type
6.4.4.4.2. Market size and forecast, by Application
6.4.4.5. South Korea
6.4.4.5.1. Market size and forecast, by Product Type
6.4.4.5.2. Market size and forecast, by Application
6.4.4.6. Rest of Asia-Pacific
6.4.4.6.1. Market size and forecast, by Product Type
6.4.4.6.2. Market size and forecast, by Application
6.5. Latin America
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by Product Type
6.5.3. Market size and forecast, by Application
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Market size and forecast, by Product Type
6.5.4.1.2. Market size and forecast, by Application
6.5.4.2. Colombia
6.5.4.2.1. Market size and forecast, by Product Type
6.5.4.2.2. Market size and forecast, by Application
6.5.4.3. Argentina
6.5.4.3.1. Market size and forecast, by Product Type
6.5.4.3.2. Market size and forecast, by Application
6.5.4.4. Rest Of La
6.5.4.4.1. Market size and forecast, by Product Type
6.5.4.4.2. Market size and forecast, by Application
6.6. Middle East and Africa
6.6.1. Key market trends, growth factors and opportunities
6.6.2. Market size and forecast, by Product Type
6.6.3. Market size and forecast, by Application
6.6.4. Market size and forecast, by country
6.6.4.1. Gcc
6.6.4.1.1. Market size and forecast, by Product Type
6.6.4.1.2. Market size and forecast, by Application
6.6.4.2. South Africa
6.6.4.2.1. Market size and forecast, by Product Type
6.6.4.2.2. Market size and forecast, by Application
6.6.4.3. North Africa
6.6.4.3.1. Market size and forecast, by Product Type
6.6.4.3.2. Market size and forecast, by Application
6.6.4.4. Rest Of Mea
6.6.4.4.1. Market size and forecast, by Product Type
6.6.4.4.2. Market size and forecast, by Application
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product mapping of top 10 player
7.4. Competitive dashboard
7.5. Competitive heatmap
7.6. Top player positioning, 2022
CHAPTER 8: COMPANY PROFILES
8.1. AbbVie Inc.
8.1.1. Company overview
8.1.2. Key executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.1.7. Key strategic moves and developments
8.2. Pfizer Inc.
8.2.1. Company overview
8.2.2. Key executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. Amgen Inc.
8.3.1. Company overview
8.3.2. Key executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. Novartis AG
8.4.1. Company overview
8.4.2. Key executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.4.7. Key strategic moves and developments
8.5. Viatris Inc.
8.5.1. Company overview
8.5.2. Key executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. Merck & Co., Inc.
8.6.1. Company overview
8.6.2. Key executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.6.7. Key strategic moves and developments
8.7. Celltrion Inc.
8.7.1. Company overview
8.7.2. Key executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. Bristol-Myers Squibb Company
8.8.1. Company overview
8.8.2. Key executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.8.7. Key strategic moves and developments
8.9. F. Hoffmann-La Roche Ltd.
8.9.1. Company overview
8.9.2. Key executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.9.7. Key strategic moves and developments
8.10. Johnson and Johnson
8.10.1. Company overview
8.10.2. Key executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
8.10.7. Key strategic moves and developments
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter s five forces analysis
3.3.1. Low threat of new entrants
3.3.2. Low threat of substitutes
3.3.3. Low bargaining power of buyers
3.3.4. Moderate bargaining power of suppliers
3.3.5. Low intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rising prevalence of arthritis globally, especially among aging populations
3.4.1.2. Increasing awareness, early diagnosis, and adoption of advanced therapies such as DMARDs and biologics
3.4.1.3. Development and adoption of biosimilars and cost-effective generic alternatives
3.4.2. Restraints
3.4.2.1. High treatment costs, especially for biologics and targeted therapies
3.4.3. Opportunities
3.4.3.1. Growth Opportunities in Emerging Markets
CHAPTER 4: ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Disease Modified Anti-rheumatoid Drugs (DMARDs)
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Biologics
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Others
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Rheumatoid Arthritis
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Osteoarthritis
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Psoriatic Arthritis
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Ankylosing Spondylitis
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Others
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
CHAPTER 6: ARTHRITIC THERAPEUTIC MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by Product Type
6.2.3. Market size and forecast, by Application
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Market size and forecast, by Product Type
6.2.4.1.2. Market size and forecast, by Application
6.2.4.2. Canada
6.2.4.2.1. Market size and forecast, by Product Type
6.2.4.2.2. Market size and forecast, by Application
6.2.4.3. Mexico
6.2.4.3.1. Market size and forecast, by Product Type
6.2.4.3.2. Market size and forecast, by Application
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by Product Type
6.3.3. Market size and forecast, by Application
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Market size and forecast, by Product Type
6.3.4.1.2. Market size and forecast, by Application
6.3.4.2. France
6.3.4.2.1. Market size and forecast, by Product Type
6.3.4.2.2. Market size and forecast, by Application
6.3.4.3. UK
6.3.4.3.1. Market size and forecast, by Product Type
6.3.4.3.2. Market size and forecast, by Application
6.3.4.4. Italy
6.3.4.4.1. Market size and forecast, by Product Type
6.3.4.4.2. Market size and forecast, by Application
6.3.4.5. Spain
6.3.4.5.1. Market size and forecast, by Product Type
6.3.4.5.2. Market size and forecast, by Application
6.3.4.6. Rest of Europe
6.3.4.6.1. Market size and forecast, by Product Type
6.3.4.6.2. Market size and forecast, by Application
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by Product Type
6.4.3. Market size and forecast, by Application
6.4.4. Market size and forecast, by country
6.4.4.1. Japan
6.4.4.1.1. Market size and forecast, by Product Type
6.4.4.1.2. Market size and forecast, by Application
6.4.4.2. China
6.4.4.2.1. Market size and forecast, by Product Type
6.4.4.2.2. Market size and forecast, by Application
6.4.4.3. India
6.4.4.3.1. Market size and forecast, by Product Type
6.4.4.3.2. Market size and forecast, by Application
6.4.4.4. Australia
6.4.4.4.1. Market size and forecast, by Product Type
6.4.4.4.2. Market size and forecast, by Application
6.4.4.5. South Korea
6.4.4.5.1. Market size and forecast, by Product Type
6.4.4.5.2. Market size and forecast, by Application
6.4.4.6. Rest of Asia-Pacific
6.4.4.6.1. Market size and forecast, by Product Type
6.4.4.6.2. Market size and forecast, by Application
6.5. Latin America
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by Product Type
6.5.3. Market size and forecast, by Application
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Market size and forecast, by Product Type
6.5.4.1.2. Market size and forecast, by Application
6.5.4.2. Colombia
6.5.4.2.1. Market size and forecast, by Product Type
6.5.4.2.2. Market size and forecast, by Application
6.5.4.3. Argentina
6.5.4.3.1. Market size and forecast, by Product Type
6.5.4.3.2. Market size and forecast, by Application
6.5.4.4. Rest Of La
6.5.4.4.1. Market size and forecast, by Product Type
6.5.4.4.2. Market size and forecast, by Application
6.6. Middle East and Africa
6.6.1. Key market trends, growth factors and opportunities
6.6.2. Market size and forecast, by Product Type
6.6.3. Market size and forecast, by Application
6.6.4. Market size and forecast, by country
6.6.4.1. Gcc
6.6.4.1.1. Market size and forecast, by Product Type
6.6.4.1.2. Market size and forecast, by Application
6.6.4.2. South Africa
6.6.4.2.1. Market size and forecast, by Product Type
6.6.4.2.2. Market size and forecast, by Application
6.6.4.3. North Africa
6.6.4.3.1. Market size and forecast, by Product Type
6.6.4.3.2. Market size and forecast, by Application
6.6.4.4. Rest Of Mea
6.6.4.4.1. Market size and forecast, by Product Type
6.6.4.4.2. Market size and forecast, by Application
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product mapping of top 10 player
7.4. Competitive dashboard
7.5. Competitive heatmap
7.6. Top player positioning, 2022
CHAPTER 8: COMPANY PROFILES
8.1. AbbVie Inc.
8.1.1. Company overview
8.1.2. Key executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.1.7. Key strategic moves and developments
8.2. Pfizer Inc.
8.2.1. Company overview
8.2.2. Key executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. Amgen Inc.
8.3.1. Company overview
8.3.2. Key executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. Novartis AG
8.4.1. Company overview
8.4.2. Key executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.4.7. Key strategic moves and developments
8.5. Viatris Inc.
8.5.1. Company overview
8.5.2. Key executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. Merck & Co., Inc.
8.6.1. Company overview
8.6.2. Key executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.6.7. Key strategic moves and developments
8.7. Celltrion Inc.
8.7.1. Company overview
8.7.2. Key executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. Bristol-Myers Squibb Company
8.8.1. Company overview
8.8.2. Key executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.8.7. Key strategic moves and developments
8.9. F. Hoffmann-La Roche Ltd.
8.9.1. Company overview
8.9.2. Key executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.9.7. Key strategic moves and developments
8.10. Johnson and Johnson
8.10.1. Company overview
8.10.2. Key executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
8.10.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 02. ARTHRITIC THERAPEUTIC MARKET FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2022-2032 ($MILLION)
TABLE 03. ARTHRITIC THERAPEUTIC MARKET FOR DISEASE MODIFIED ANTI-RHEUMATOID DRUGS (DMARDS), BY REGION, 2022-2032 ($MILLION)
TABLE 04. ARTHRITIC THERAPEUTIC MARKET FOR BIOLOGICS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. ARTHRITIC THERAPEUTIC MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 06. GLOBAL ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 07. ARTHRITIC THERAPEUTIC MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2022-2032 ($MILLION)
TABLE 08. ARTHRITIC THERAPEUTIC MARKET FOR OSTEOARTHRITIS, BY REGION, 2022-2032 ($MILLION)
TABLE 09. ARTHRITIC THERAPEUTIC MARKET FOR PSORIATIC ARTHRITIS, BY REGION, 2022-2032 ($MILLION)
TABLE 10. ARTHRITIC THERAPEUTIC MARKET FOR ANKYLOSING SPONDYLITIS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. ARTHRITIC THERAPEUTIC MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 12. ARTHRITIC THERAPEUTIC MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 13. NORTH AMERICA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA ARTHRITIC THERAPEUTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 16. U.S. ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 17. U.S. ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 18. CANADA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 19. CANADA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 20. MEXICO ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 21. MEXICO ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 22. EUROPE ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 23. EUROPE ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 24. EUROPE ARTHRITIC THERAPEUTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 25. GERMANY ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 26. GERMANY ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 27. FRANCE ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 28. FRANCE ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 29. UK ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 30. UK ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 31. ITALY ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 32. ITALY ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 33. SPAIN ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 34. SPAIN ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 35. REST OF EUROPE ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 36. REST OF EUROPE ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 37. ASIA-PACIFIC ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 38. ASIA-PACIFIC ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 39. ASIA-PACIFIC ARTHRITIC THERAPEUTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 40. JAPAN ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 41. JAPAN ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 42. CHINA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 43. CHINA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 44. INDIA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 45. INDIA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 46. AUSTRALIA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 47. AUSTRALIA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 48. SOUTH KOREA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 49. SOUTH KOREA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 50. REST OF ASIA-PACIFIC ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 51. REST OF ASIA-PACIFIC ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 52. LATIN AMERICA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 53. LATIN AMERICA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 54. LATIN AMERICA ARTHRITIC THERAPEUTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 55. BRAZIL ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 56. BRAZIL ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 57. COLOMBIA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 58. COLOMBIA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 59. ARGENTINA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 60. ARGENTINA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 61. REST OF LA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 62. REST OF LA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 63. MIDDLE EAST AND AFRICA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 64. MIDDLE EAST AND AFRICA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 65. MIDDLE EAST AND AFRICA ARTHRITIC THERAPEUTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 66. GCC ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 67. GCC ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 68. SOUTH AFRICA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 69. SOUTH AFRICA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 70. NORTH AFRICA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 71. NORTH AFRICA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 72. REST OF MEA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 73. REST OF MEA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 74. ABBVIE INC.: KEY EXECUTIVES
TABLE 75. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 76. ABBVIE INC.: PRODUCT SEGMENTS
TABLE 77. ABBVIE INC.: SERVICE SEGMENTS
TABLE 78. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 79. ABBVIE INC.: KEY STRATERGIES
TABLE 80. PFIZER INC.: KEY EXECUTIVES
TABLE 81. PFIZER INC.: COMPANY SNAPSHOT
TABLE 82. PFIZER INC.: PRODUCT SEGMENTS
TABLE 83. PFIZER INC.: SERVICE SEGMENTS
TABLE 84. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 85. PFIZER INC.: KEY STRATERGIES
TABLE 86. AMGEN INC.: KEY EXECUTIVES
TABLE 87. AMGEN INC.: COMPANY SNAPSHOT
TABLE 88. AMGEN INC.: PRODUCT SEGMENTS
TABLE 89. AMGEN INC.: SERVICE SEGMENTS
TABLE 90. AMGEN INC.: PRODUCT PORTFOLIO
TABLE 91. AMGEN INC.: KEY STRATERGIES
TABLE 92. NOVARTIS AG: KEY EXECUTIVES
TABLE 93. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 94. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 95. NOVARTIS AG: SERVICE SEGMENTS
TABLE 96. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 97. NOVARTIS AG: KEY STRATERGIES
TABLE 98. VIATRIS INC.: KEY EXECUTIVES
TABLE 99. VIATRIS INC.: COMPANY SNAPSHOT
TABLE 100. VIATRIS INC.: PRODUCT SEGMENTS
TABLE 101. VIATRIS INC.: SERVICE SEGMENTS
TABLE 102. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 103. VIATRIS INC.: KEY STRATERGIES
TABLE 104. MERCK & CO., INC.: KEY EXECUTIVES
TABLE 105. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 106. MERCK & CO., INC.: PRODUCT SEGMENTS
TABLE 107. MERCK & CO., INC.: SERVICE SEGMENTS
TABLE 108. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 109. MERCK & CO., INC.: KEY STRATERGIES
TABLE 110. CELLTRION INC.: KEY EXECUTIVES
TABLE 111. CELLTRION INC.: COMPANY SNAPSHOT
TABLE 112. CELLTRION INC.: PRODUCT SEGMENTS
TABLE 113. CELLTRION INC.: SERVICE SEGMENTS
TABLE 114. CELLTRION INC.: PRODUCT PORTFOLIO
TABLE 115. CELLTRION INC.: KEY STRATERGIES
TABLE 116. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
TABLE 117. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 118. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
TABLE 119. BRISTOL-MYERS SQUIBB COMPANY: SERVICE SEGMENTS
TABLE 120. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 121. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES
TABLE 122. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 123. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 124. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 125. F. HOFFMANN-LA ROCHE LTD.: SERVICE SEGMENTS
TABLE 126. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 127. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
TABLE 128. JOHNSON AND JOHNSON: KEY EXECUTIVES
TABLE 129. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
TABLE 130. JOHNSON AND JOHNSON: PRODUCT SEGMENTS
TABLE 131. JOHNSON AND JOHNSON: SERVICE SEGMENTS
TABLE 132. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
TABLE 133. JOHNSON AND JOHNSON: KEY STRATERGIES
TABLE 01. GLOBAL ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 02. ARTHRITIC THERAPEUTIC MARKET FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2022-2032 ($MILLION)
TABLE 03. ARTHRITIC THERAPEUTIC MARKET FOR DISEASE MODIFIED ANTI-RHEUMATOID DRUGS (DMARDS), BY REGION, 2022-2032 ($MILLION)
TABLE 04. ARTHRITIC THERAPEUTIC MARKET FOR BIOLOGICS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. ARTHRITIC THERAPEUTIC MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 06. GLOBAL ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 07. ARTHRITIC THERAPEUTIC MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2022-2032 ($MILLION)
TABLE 08. ARTHRITIC THERAPEUTIC MARKET FOR OSTEOARTHRITIS, BY REGION, 2022-2032 ($MILLION)
TABLE 09. ARTHRITIC THERAPEUTIC MARKET FOR PSORIATIC ARTHRITIS, BY REGION, 2022-2032 ($MILLION)
TABLE 10. ARTHRITIC THERAPEUTIC MARKET FOR ANKYLOSING SPONDYLITIS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. ARTHRITIC THERAPEUTIC MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 12. ARTHRITIC THERAPEUTIC MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 13. NORTH AMERICA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA ARTHRITIC THERAPEUTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 16. U.S. ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 17. U.S. ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 18. CANADA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 19. CANADA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 20. MEXICO ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 21. MEXICO ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 22. EUROPE ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 23. EUROPE ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 24. EUROPE ARTHRITIC THERAPEUTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 25. GERMANY ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 26. GERMANY ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 27. FRANCE ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 28. FRANCE ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 29. UK ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 30. UK ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 31. ITALY ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 32. ITALY ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 33. SPAIN ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 34. SPAIN ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 35. REST OF EUROPE ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 36. REST OF EUROPE ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 37. ASIA-PACIFIC ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 38. ASIA-PACIFIC ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 39. ASIA-PACIFIC ARTHRITIC THERAPEUTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 40. JAPAN ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 41. JAPAN ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 42. CHINA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 43. CHINA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 44. INDIA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 45. INDIA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 46. AUSTRALIA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 47. AUSTRALIA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 48. SOUTH KOREA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 49. SOUTH KOREA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 50. REST OF ASIA-PACIFIC ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 51. REST OF ASIA-PACIFIC ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 52. LATIN AMERICA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 53. LATIN AMERICA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 54. LATIN AMERICA ARTHRITIC THERAPEUTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 55. BRAZIL ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 56. BRAZIL ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 57. COLOMBIA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 58. COLOMBIA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 59. ARGENTINA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 60. ARGENTINA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 61. REST OF LA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 62. REST OF LA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 63. MIDDLE EAST AND AFRICA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 64. MIDDLE EAST AND AFRICA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 65. MIDDLE EAST AND AFRICA ARTHRITIC THERAPEUTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 66. GCC ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 67. GCC ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 68. SOUTH AFRICA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 69. SOUTH AFRICA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 70. NORTH AFRICA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 71. NORTH AFRICA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 72. REST OF MEA ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 73. REST OF MEA ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 74. ABBVIE INC.: KEY EXECUTIVES
TABLE 75. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 76. ABBVIE INC.: PRODUCT SEGMENTS
TABLE 77. ABBVIE INC.: SERVICE SEGMENTS
TABLE 78. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 79. ABBVIE INC.: KEY STRATERGIES
TABLE 80. PFIZER INC.: KEY EXECUTIVES
TABLE 81. PFIZER INC.: COMPANY SNAPSHOT
TABLE 82. PFIZER INC.: PRODUCT SEGMENTS
TABLE 83. PFIZER INC.: SERVICE SEGMENTS
TABLE 84. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 85. PFIZER INC.: KEY STRATERGIES
TABLE 86. AMGEN INC.: KEY EXECUTIVES
TABLE 87. AMGEN INC.: COMPANY SNAPSHOT
TABLE 88. AMGEN INC.: PRODUCT SEGMENTS
TABLE 89. AMGEN INC.: SERVICE SEGMENTS
TABLE 90. AMGEN INC.: PRODUCT PORTFOLIO
TABLE 91. AMGEN INC.: KEY STRATERGIES
TABLE 92. NOVARTIS AG: KEY EXECUTIVES
TABLE 93. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 94. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 95. NOVARTIS AG: SERVICE SEGMENTS
TABLE 96. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 97. NOVARTIS AG: KEY STRATERGIES
TABLE 98. VIATRIS INC.: KEY EXECUTIVES
TABLE 99. VIATRIS INC.: COMPANY SNAPSHOT
TABLE 100. VIATRIS INC.: PRODUCT SEGMENTS
TABLE 101. VIATRIS INC.: SERVICE SEGMENTS
TABLE 102. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 103. VIATRIS INC.: KEY STRATERGIES
TABLE 104. MERCK & CO., INC.: KEY EXECUTIVES
TABLE 105. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 106. MERCK & CO., INC.: PRODUCT SEGMENTS
TABLE 107. MERCK & CO., INC.: SERVICE SEGMENTS
TABLE 108. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 109. MERCK & CO., INC.: KEY STRATERGIES
TABLE 110. CELLTRION INC.: KEY EXECUTIVES
TABLE 111. CELLTRION INC.: COMPANY SNAPSHOT
TABLE 112. CELLTRION INC.: PRODUCT SEGMENTS
TABLE 113. CELLTRION INC.: SERVICE SEGMENTS
TABLE 114. CELLTRION INC.: PRODUCT PORTFOLIO
TABLE 115. CELLTRION INC.: KEY STRATERGIES
TABLE 116. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
TABLE 117. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 118. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
TABLE 119. BRISTOL-MYERS SQUIBB COMPANY: SERVICE SEGMENTS
TABLE 120. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 121. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES
TABLE 122. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 123. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 124. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 125. F. HOFFMANN-LA ROCHE LTD.: SERVICE SEGMENTS
TABLE 126. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 127. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
TABLE 128. JOHNSON AND JOHNSON: KEY EXECUTIVES
TABLE 129. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
TABLE 130. JOHNSON AND JOHNSON: PRODUCT SEGMENTS
TABLE 131. JOHNSON AND JOHNSON: SERVICE SEGMENTS
TABLE 132. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
TABLE 133. JOHNSON AND JOHNSON: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. ARTHRITIC THERAPEUTIC MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF ARTHRITIC THERAPEUTIC MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN ARTHRITIC THERAPEUTIC MARKET (2022 TO 2032)
FIGURE 04. TOP INVESTMENT POCKETS IN ARTHRITIC THERAPEUTIC MARKET (2023-2032)
FIGURE 05. LOW THREAT OF NEW ENTRANTS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. LOW BARGAINING POWER OF BUYERS
FIGURE 08. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 09. LOW INTENSITY OF RIVALRY
FIGURE 10. GLOBAL ARTHRITIC THERAPEUTIC MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ARTHRITIC THERAPEUTIC MARKET FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ARTHRITIC THERAPEUTIC MARKET FOR DISEASE MODIFIED ANTI-RHEUMATOID DRUGS (DMARDS), BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ARTHRITIC THERAPEUTIC MARKET FOR BIOLOGICS, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ARTHRITIC THERAPEUTIC MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ARTHRITIC THERAPEUTIC MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ARTHRITIC THERAPEUTIC MARKET FOR OSTEOARTHRITIS, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ARTHRITIC THERAPEUTIC MARKET FOR PSORIATIC ARTHRITIS, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ARTHRITIC THERAPEUTIC MARKET FOR ANKYLOSING SPONDYLITIS, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF ARTHRITIC THERAPEUTIC MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. ARTHRITIC THERAPEUTIC MARKET BY REGION, 2022 AND 2032(%)
FIGURE 23. U.S. ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 24. CANADA ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 25. MEXICO ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 26. GERMANY ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 27. FRANCE ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 28. UK ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 29. ITALY ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 30. SPAIN ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 31. REST OF EUROPE ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 32. JAPAN ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 33. CHINA ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 34. INDIA ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 35. AUSTRALIA ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 36. SOUTH KOREA ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 37. REST OF ASIA-PACIFIC ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 38. BRAZIL ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 39. COLOMBIA ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 40. ARGENTINA ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 41. REST OF LA ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 42. GCC ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 43. SOUTH AFRICA ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 44. NORTH AFRICA ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 45. REST OF MEA ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 46. TOP WINNING STRATEGIES, BY YEAR (2023-2025)
FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT (2023-2025)
FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY (2023-2025)
FIGURE 49. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 50. COMPETITIVE DASHBOARD
FIGURE 51. COMPETITIVE HEATMAP: ARTHRITIC THERAPEUTIC MARKET
FIGURE 52. TOP PLAYER POSITIONING, 2022
FIGURE 01. ARTHRITIC THERAPEUTIC MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF ARTHRITIC THERAPEUTIC MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN ARTHRITIC THERAPEUTIC MARKET (2022 TO 2032)
FIGURE 04. TOP INVESTMENT POCKETS IN ARTHRITIC THERAPEUTIC MARKET (2023-2032)
FIGURE 05. LOW THREAT OF NEW ENTRANTS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. LOW BARGAINING POWER OF BUYERS
FIGURE 08. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 09. LOW INTENSITY OF RIVALRY
FIGURE 10. GLOBAL ARTHRITIC THERAPEUTIC MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ARTHRITIC THERAPEUTIC MARKET FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ARTHRITIC THERAPEUTIC MARKET FOR DISEASE MODIFIED ANTI-RHEUMATOID DRUGS (DMARDS), BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ARTHRITIC THERAPEUTIC MARKET FOR BIOLOGICS, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ARTHRITIC THERAPEUTIC MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION, 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ARTHRITIC THERAPEUTIC MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ARTHRITIC THERAPEUTIC MARKET FOR OSTEOARTHRITIS, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ARTHRITIC THERAPEUTIC MARKET FOR PSORIATIC ARTHRITIS, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ARTHRITIC THERAPEUTIC MARKET FOR ANKYLOSING SPONDYLITIS, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF ARTHRITIC THERAPEUTIC MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. ARTHRITIC THERAPEUTIC MARKET BY REGION, 2022 AND 2032(%)
FIGURE 23. U.S. ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 24. CANADA ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 25. MEXICO ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 26. GERMANY ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 27. FRANCE ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 28. UK ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 29. ITALY ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 30. SPAIN ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 31. REST OF EUROPE ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 32. JAPAN ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 33. CHINA ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 34. INDIA ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 35. AUSTRALIA ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 36. SOUTH KOREA ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 37. REST OF ASIA-PACIFIC ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 38. BRAZIL ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 39. COLOMBIA ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 40. ARGENTINA ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 41. REST OF LA ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 42. GCC ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 43. SOUTH AFRICA ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 44. NORTH AFRICA ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 45. REST OF MEA ARTHRITIC THERAPEUTIC MARKET, 2022-2032 ($MILLION)
FIGURE 46. TOP WINNING STRATEGIES, BY YEAR (2023-2025)
FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT (2023-2025)
FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY (2023-2025)
FIGURE 49. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 50. COMPETITIVE DASHBOARD
FIGURE 51. COMPETITIVE HEATMAP: ARTHRITIC THERAPEUTIC MARKET
FIGURE 52. TOP PLAYER POSITIONING, 2022
